-
平臺(tái)編號(hào)：bio-69582
-
國際編號(hào)：CRL-5898?
-
細(xì)胞信息： NCI-H1836
-
規(guī)格：Frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
NCI-H1836
運(yùn)輸方式：凍存運(yùn)輸
年限：stage L
ATCC Number：CRL-5898?
相關(guān)疾?。盒〖?xì)胞肺癌
器官來源：肺
是否是腫瘤細(xì)胞：1
物種來源：人
數(shù)量：大量
生長(zhǎng)狀態(tài)：漂浮生長(zhǎng)
規(guī)格：300 ul Designations: NCI-H1836 [H1836]
Depositors: ?AF Gazdar, JD Minna
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:floating aggregates of round cell clusters
Organism: Homo sapiens
Morphology:
Source: Organ: lung
Tumor Stage: stage L
Disease: carcinoma; classic small cell lung cancer
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.
DNA Profile (STR):Amelogenin: X
CSF1PO: 12
D13S317: 10,12
D16S539: 11,13
D5S818: 11
D7S820: 11,12
THO1: 8,9.3
TPOX: 9,10
vWA: 16
Cytogenetic Analysis:del(p11-qter)
Age: 52 years
Gender: male
Ethnicity: Caucasian
Comments:The line was established in February 1988.
The patient received prior chemotherapy and radiation therapy.
The patient was a smoker.
38 pack years.
Propagation: ATCC complete growth medium: HITES medium supplemented with 5% fetal bovine serum
Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium as cell density increases.
Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively the cells may be collected by centrifugation with subsequent resuspension in fresh medium.
Preservation: culture medium, 90%; additional fetal bovine serum, 5%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2006
recommended serum:ATCC 30-2020
References: 23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996..
年限：stage L
ATCC Number：CRL-5898?
相關(guān)疾?。盒〖?xì)胞肺癌
器官來源：肺
是否是腫瘤細(xì)胞：1
物種來源：人
數(shù)量：大量
生長(zhǎng)狀態(tài)：漂浮生長(zhǎng)
規(guī)格：300 ul Designations: NCI-H1836 [H1836]
Depositors: ?AF Gazdar, JD Minna
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:floating aggregates of round cell clusters
Organism: Homo sapiens
Morphology:
Source: Organ: lung
Tumor Stage: stage L
Disease: carcinoma; classic small cell lung cancer
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.
DNA Profile (STR):Amelogenin: X
CSF1PO: 12
D13S317: 10,12
D16S539: 11,13
D5S818: 11
D7S820: 11,12
THO1: 8,9.3
TPOX: 9,10
vWA: 16
Cytogenetic Analysis:del(p11-qter)
Age: 52 years
Gender: male
Ethnicity: Caucasian
Comments:The line was established in February 1988.
The patient received prior chemotherapy and radiation therapy.
The patient was a smoker.
38 pack years.
Propagation: ATCC complete growth medium: HITES medium supplemented with 5% fetal bovine serum
-
The base medium for this cell line is ATCC-formulated DMEM:F12 Medium Catalog No.30-2006. To make the complete growth medium,add the following components to the base medium
- 0.005 mg/ml Insulin
- 0.01 mg/ml Transferrin
- 30nM Sodium selenite (final conc.)
- 10 nM Hydrocortisone (final conc.)
- 10 nM beta-estradiol (final conc.)
- extra 2mM L-glutamine (for final conc. of 4.5 mM)
- 5% fetal bovine serum (final conc.)
Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium as cell density increases.
Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively the cells may be collected by centrifugation with subsequent resuspension in fresh medium.
Preservation: culture medium, 90%; additional fetal bovine serum, 5%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2006
recommended serum:ATCC 30-2020
References: 23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996..
